CollPlant Biotechnologies (CLGN) is up 62.0% today. Here is some analysis on what might have caused this price movement.
Analysis: The sharp move appears tied to CollPlant’s August 31 announcement that it signed a definitive agreement to acquire LightSolver, a laser-based photonic computing company. Investors likely viewed the deal as a dramatic expansion beyond regenerative medicine into supercomputing and high-performance computing, creating a new growth narrative for a microcap stock.
Details:
Sources:
CollPlant Investor Relations, SEC, PR Newswire
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$CLGN Hedge Fund Activity
We have seen 4 institutional investors add shares of $CLGN stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PINNACLE ASSOCIATES LTD added 181,434 shares (+33.0%) to their portfolio in Q2 2026, for an estimated $63,302
- ARMISTICE CAPITAL, LLC removed 64,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,329
- RENAISSANCE TECHNOLOGIES LLC added 44,700 shares (+266.1%) to their portfolio in Q2 2026, for an estimated $15,595
- CITADEL ADVISORS LLC added 21,535 shares (+67.0%) to their portfolio in Q2 2026, for an estimated $7,513
- BROWN ADVISORY INC removed 14,000 shares (-11.8%) from their portfolio in Q2 2026, for an estimated $4,884
- VIRTU FINANCIAL LLC removed 12,600 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $4,396
- TWO SIGMA SECURITIES, LLC removed 11,357 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $3,962
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.